BPC-157 vs CJC-1295 with DAC
Extensively Studied vs Well Studied
synergistic Mechanism-based · 47% BPC-157 and CJC-1295 with DAC work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
BPC-157 CJC-1295 with DAC
Weight 1,419.53 Da 3,647.28 Da
Half-life <30 minutes 6-8 days
Chain 15 amino acids 30 amino acids
Type Pentadecapeptide GHRH analog with DAC
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Diabetes history
Cancer history
Predisposed sleep apnea
Research Evidence
BPC-157 CJC-1295 with DAC
Status Extensively Studied Well Studied
References 8 studies 4 studies
Latest July 2025 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.